sulfinpyrazone has been researched along with tolbutamide in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (35.71) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Ekins, S; Harwood, HJ; Hoover, DJ; Lawton, MP; Mankowski, DC; Treadway, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Buttar, D; Colclough, N; Gerhardt, S; MacFaul, PA; Maskos, K; Phillips, SD; Plowright, A; Steinbacher, S; Steuber, H; Tam, K; Whittamore, P | 1 |
| Sellers, E; Weser, JK | 1 |
| Duckert, F; Seiler, K | 1 |
| Birkett, DJ; Foenander, T; Gallus, AS; Miners, JO; Wanwimolruk, S | 1 |
| Byington, KH; Ryan, MP; Wosilait, WD | 1 |
| KUNIN, CM | 1 |
1 review(s) available for sulfinpyrazone and tolbutamide
| Article | Year |
|---|---|
Drug interactions with coumarin anticoagulants. 2.
Topics: Allopurinol; Anabolic Agents; Animals; Anti-Bacterial Agents; Anticoagulants; Barbiturates; Chloral Hydrate; Chloramphenicol; Cholestyramine Resin; Clofibrate; Contraceptives, Oral; Coumarins; Dextrothyroxine; Diuretics; Drug Antagonism; Drug Synergism; Ethacrynic Acid; Ethanol; Glucagon; Glucocorticoids; Glutethimide; Humans; Oxyphenbutazone; Phenylbutazone; Quinidine; Quinine; Quinolines; Salicylates; Sulfinpyrazone; Sulfonamides; Thyroid Hormones; Tolbutamide | 1971 |
13 other study(ies) available for sulfinpyrazone and tolbutamide
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors.
Topics: Amides; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Humans; Indoles; Models, Molecular; Oxidoreductases; Quantitative Structure-Activity Relationship; Sterol 14-Demethylase | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
Topics: Binding Sites; Crystallography, X-Ray; Drug Interactions; Humans; Pharmaceutical Preparations; Protein Binding; Protein Structure, Tertiary; Serum Albumin; Spectrometry, Fluorescence | 2010 |
Properties of 3-(1-phenyl-propyl)-4-oxycoumarin (marcoumar) in the plasma when tested in normal cases and under the influence of drugs.
Topics: Blood Proteins; Coumarins; Drug Synergism; Ethyl Biscoumacetate; Fluorometry; Phenobarbital; Phenylbutazone; Protein Binding; Spectrophotometry; Sulfadimethoxine; Sulfinpyrazone; Tolbutamide | 1968 |
The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination.
Topics: Adult; Blood Proteins; Drug Interactions; Humans; In Vitro Techniques; Male; Metabolic Clearance Rate; Protein Binding; Sulfinpyrazone; Tolbutamide; Warfarin | 1982 |
Competition between serum albumin and soluble fraction of liver for binding of warfarin and other drugs.
Topics: Animals; Binding, Competitive; Humans; In Vitro Techniques; Iopanoic Acid; Liver; Male; Rats; Serum Albumin; Sulfinpyrazone; Tolbutamide; Warfarin | 1981 |
INHIBITORS OF PENICILLIN BINDING TO SERUM PROTEINS.
Topics: Acetazolamide; Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antimetabolites; Aspirin; Benzoates; Biguanides; Blood Proteins; Carbon Isotopes; Chlorothiazide; Diuretics; Ethacrynic Acid; Guanidines; Oxazoles; p-Aminohippuric Acid; Penicillin G; Penicillin V; Penicillins; Pharmacology; Phenylbutazone; Probenecid; Rabbits; Research; Salicylates; Sulfinpyrazone; Sulfonamides; Tolbutamide | 1965 |